Two years ago: Thailand reports first case of Covid-19 outside China

On January 3, a few days after authorities reported a cluster of atypical pneumonia in Wuhan, Thailand started to screen passengers from China for symptoms of acute respiratory infection.

Thailand raises to level 4 alert for COVID-19

Thailand’s COVID-19 alert has been raised from Level 3 to Level 4 today (Thursday), with more restrictive measures to be announced in the near future, according to Public Health Permanent Secretary Kiattibhoom Vongrachit.

SET contributes THB 40 million to locally developed Covid -19 vaccine

The donation is in accordance with SET’s intention to promote Thai innovations that can lead to tangible results, and the vaccine development projects are also in line with SET’s vision “To Make the Capital Market ‘Work’ for Everyone”.

Omicron: Thai expert predicts more cases but with possible herd Immunity

Dr Manoon believes the Omicron strain will eventually infect everyone, whether they have been vaccinated or not, causing entire populations to achieve herd immunity. He suggests that the variant will operate as a live attenuated vaccine, delivering stronger immunity stimulation than existing COVID vaccines.

Emerging Market Trends: global cooperation increased in 2021

Following on from a year in which supply chains and international travel were severely disrupted, 2021 saw an increase in global cooperation, as institutions, businesses and governments alike sought to work together to find solutions to some of the world’s major challenges.

Thailand further eases COVID-19 curbs nationwide, allowing New Year countdown festivities

The New Year countdown festivities will be allowed to take place under the COVID-free setting guidelines, which include vaccination requirement, universal prevention, health and hygiene measures, and antigen testing.

Vietnam to Increase Production of Russia’s COVID-19 Vaccine

An initial investment of around US$60-US$70 million will enable the technical implementation of the project to begin in early 2022 before full-fledged production starts in early 2023. The facility is expected to produce some 40 million doses of the two-component vaccine per year.